# US 2015/0147301 A1 · Methods and compositions of producing patient-specific multipotent neuronal stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147301 A1
- Document ID: US20150147301A1
- Status: Published application
- Kind: A1
- Application number: 14/591,764
- Filed: 2015-01-07
- Published: 2015-05-28
- Earliest claimed: 2011-02-14
- Assignees: International Stem Cell Corporation
- Applicants: International Stem Cell Corporation
- Inventors: Ruslan Semechkin; Dmitry Isaev
- Web page: https://patentgrep.com/patent/US20150147301A1

## CPC

- C12N 5/0623: {Stem cells}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- C12N 5/0618: {Cells of the nervous system}
- C12N 5/0619: {Neurons}
- C12N 2500/32: Amino acids
- C12N 2500/46: Amines, e.g. putrescine
- C12N 2500/70: Undefined extracts
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2506/02: from embryonic cells
- C12N 2506/04: from germ cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to the seminal discovery of compositions and a method of producing NSC obtained from stem cells derived from parthenogenically activated human oocytes (phNSC). The phNSC of the invention maintain proliferative and differentiation potential during cultivation and expansion.

## Claims

### Claim 1

An isolated neuronal stem cell, wherein the cell is differentiated from a parthenogenetically activated oocyte.

### Claim 2 (depends on 1)

The neuronal stem cell of claim 1, wherein the cell is histocompatible with the oocyte donor.

### Claim 3 (depends on 2)

The neuronal stem cell of claim 2, wherein the cell is histocompatible with a population group based on a matching haplotype.

### Claim 4 (depends on 1)

The neuronal stem cell of claim 1, wherein the cell has a different pattern of zygosity from an ESC.

### Claim 5 (depends on 1)

The neuronal stem cell of claim 1, wherein the cell contains only the maternal genome.

### Claim 6 (depends on 1)

The neuronal stem cell of claim 1, wherein the cell is histocompatible with the oocyte donor, has a different pattern of zygosity from an ESC and contains only the maternal genome.

### Claim 7 (depends on 1)

The neuronal stem cell of claim 1, wherein the cell is transplantable to humans.

### Claim 8 (depends on 1)

The neuronal stem cell of claim 1, wherein the cell is undifferentiated, partially differentiated or fully differentiated.

### Claim 9 (depends on 1)

The neuronal stem cell of claim 1, wherein the cell can be differentiated into a neuronal cell.

### Claim 10 (depends on 9)

The neuronal stem cell of claim 9, wherein the cell can be differentiated a neuronal cell selected from the group consisting of a neuron, a glial cell, an oligodendrocyte and an astrocyte.

### Claim 11 (depends on 10)

The differentiated neuronal cell of claim 10, wherein the cell is a neuron.

### Claim 12 (depends on 11)

The neuron of claim 11, wherein the neuron is selected from the group consisting of: a cholinergic neuron, a GABAergic neuron, a glutamatergic neuron, a dopaminergic neuron and a serotonergic neuron.

### Claim 13 (depends on 12)

The neuron of claim 12, wherein the neuron is a dopaminergic neuron.

### Claim 14 (depends on 1)

The neuronal stem cell of claim 1, wherein the cell express neural markers selected from the group consisting of: SOX2, Nestin, Mushashi-1, TUBB3, MAP2, FOXO4, GFAP, CD113 and CD15

### Claim 15

A method for producing a neuronal stem cells by differentiating parthenogenetically derived human stem cells, the method comprising:
a) growing parthenogenetically derived human stem cells on a feeder layer of fibroblast cells for at least 2 days;
b) growing parthenogenetically derived human stem cells on a petri dish without fibroblast feeder layer for at least 1 day;
c) culturing the cells in a neuronal induction media;
d) obtaining a single cell suspension of the cells from (c); and
e) culturing the single cells from step (d) on a petri dish with no fibroblast feeder layer in a neuronal proliferation media.

### Claim 16 (depends on 15)

The method of claim 15, wherein the neuronal induction media comprises:
a) Penicillin-Streptomycin-Amphotericin Solution
b) DMEM/F12;
c) MEM Non-Essential Amino Acids Solution;
d) L-Glutamine;
e) N2 Supplement; and
f) bFGF.

### Claim 17 (depends on 15)

The method of claim 15, wherein the neuronal proliferation media comprises:
a) Penicillin-Streptomycin-Amphotericin;
b) DMEM/F12;
c) GlutaMAX™-I;
d) StemPro® Neural Supplement;
e) bFGF; and
f) EGF.

### Claim 18 (depends on 15)

The method of claim 15, wherein the petri dish is coated with CELLstart.

### Claim 19 (depends on 15)

A neuronal stem cell produced by the method of claim 15.

### Claim 20 (depends on 15)

The method of claim 15, wherein a neuroepithelial rosette forms in about 1-2 weeks.

### Claim 21

Isolated neuronal stem cells derived from parthenogenetically derived human stem cells using the method comprising:
a) growing parthenogenetically derived human stem cells on a feeder layer of fibroblast cells for at least 2 days;
b) growing parthenogenetically derived human stem cells on a petri dish with no fibroblast feeder layer for at least 1 day;
c) culturing the cells in a neuronal induction media;
d) obtaining a single cell suspension of the cells from (c); and
e) culturing the single cells from step (d) on a petri dish with no fibroblast feeder layer in a neuronal proliferation media.

### Claim 22 (depends on 21)

The cells of claim 21, wherein the cells express neural markers selected from the group consisting of: SOX2, Nestin, Mushashi-1, TUBB3, MAP2, FOXO4, GFAP, CD113 and CD15.

### Claim 23 (depends on 21)

The cells of claim 21, wherein the neuronal stem cells maintain the neuronal phenotype for at least 27 passages.

### Claim 24 (depends on 21)

The cells of claim 21, wherein the neuronal stem cells can differentiate into neuronal cells.

### Claim 25 (depends on 24)

The cells of claim 24, wherein the neuronal cells are selected from the group consisting of neurons, glial cells, astrocytes and oligodendrocytes.

### Claim 26 (depends on 25)

The differentiated neuronal cell of claim 25, wherein the cell is a neuron.

### Claim 27 (depends on 26)

The neuron of claim 26, wherein the neuron is selected from the group consisting of: a cholinergic neuron, a GABAergic neuron, a glutamatergic neuron, a dopaminergic neuron and a serotonergic neuron.

### Claim 28 (depends on 27)

The neuron of claim 27, wherein the neuron is a dopaminergic neuron.

### Claim 29 (depends on 21)

The cells of claim 21, wherein the cell is histocompatible with the oocyte donor.

### Claim 30 (depends on 21)

The cells of claim 21, wherein the cell has a different pattern of zygosity from an ESC.

### Claim 31 (depends on 21)

The cells of claim 21, wherein the cell contains only the maternal genome.

### Claim 32 (depends on 21)

The neuronal stem cell of claim 21, wherein the cell is histocompatible with the oocyte donor, has a different pattern of zygosity from an ESC and contains only the maternal genome.

### Claim 33 (depends on 21)

The neuronal stem cell of claim 21, wherein the cell is transplantable to humans.

### Claim 34

A method of treating a neurologic disorder using neuronal stem cells produced from parthenogenetically derived from oocytes.

### Claim 35 (depends on 34)

The method of claim 34, wherein the neurologic disorder is selected from the group consisting of: epilepsy, convulsions, neurotoxic injury, hypoxia, anoxia, ischemia, stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drowning, suffocation, perinatal asphyxia, hypoglycemic events, neurodegeneration, Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease, schizophrenia, AIDS dementia, multi-infarct dementia, Binswanger dementia, neuronal damage, seizures, chemical toxicity, addiction, morphine tolerance, opiate tolerance, opioid tolerance, barbiturate tolerance, acute and chronic pain, migraine, anxiety, major depression, manic-depressive illness, obsessive-compulsive disorder, schizophrenia and mood disorders, bipolar disorder, unipolar depression, dysthymia, seasonal effective disorder, dystonia or other movement disorders, sleep disorder, muscle relaxation and urinary incontinence.

### Claim 36 (depends on 34)

The method of claim 34, wherein the neuronal stem cells are implanted into a patient in need of such treatment.

### Claim 37

A method of differentiating neuronal stem cells, the method comprising culturing neuronal stem cells in neuronal differentiation media.

### Claim 38 (depends on 37)

The method of claim 37, wherein the neuronal differentiation media comprises:
a) Penicillin-Streptomycin-Amphotericin;
b) DMEM/F12;
c) GlutaMAX™-I; and
d) StemPro® Neural Supplement.

### Claim 39 (depends on 37)

The method of claim 37 wherein the neuronal stem cells are differentiated into a neuronal cell selected from the group consisting of: a neuron, a glial cell, an oligodendrocyte and an astrocyte.

### Claim 40 (depends on 39)

The differentiated neuronal cell of claim 39, wherein the cell is a neuron.

### Claim 41 (depends on 40)

The neuron of claim 40, wherein the neuron is selected from the group consisting of: a cholinergic neuron, a GABAergic neuron, a glutamatergic neuron, a dopaminergic neuron and a serotonergic neuron.

### Claim 42 (depends on 41)

The neuron of claim 41, wherein the neuron is a dopaminergic neuron.

### Claim 43 (depends on 37)

Differentiated cells produced by the method of claim 37.

### Claim 44 (depends on 37)

The cells of claim 37, wherein the cells are differentiated from a parthenogenetically activated oocyte.

### Claim 45

A method for producing neuronal stem cells by differentiating parthenogenetically derived human stem cells, the method comprising:
a) cultivation of human pluripotent stem cells in feeder-free conditions;
b) exposure of said cells to neuronal induction medium;
c) mechanical isolation of partially differentiated cells; and
d) further expansion and maintenance of said cells until maturation.

### Claim 46 (depends on 45)

The method of claim 45, wherein the neuronal induction media comprises:
a) Penicillin-Streptomycin-Amphotericin Solution;
b) DMEM/F12;
c) MEM Non-Essential Amino Acids Solution;
d) L-Glutamine;
e) N2 Supplement; and
f) bFGF.

### Claim 47 (depends on 45)

The method of claim 45, wherein the neuronal proliferation media comprises:
a) Penicillin-Streptomycin-Amphotericin;
b) DMEM/F12;
c) GlutaMAX™-I;
d) StemPro® Neural Supplement;
e) bFGF; and
f) EGF.

### Claim 48 (depends on 45)

The method of claim 45, wherein feeder-free conditions utilize the ECM substrate including but not limited to: CELLstart, Matrigel, laminin, gelatin, fibronectin.

### Claim 49 (depends on 45)

The neuronal stem cell of claim 45.

### Claim 50 (depends on 45)

The method of claim 45, wherein a neuroepithelial rosette forms after 1-2 weeks.

### Claim 51

Isolate neuronal stem cells derived from parthenogenetically derived human stem cells using the method comprising:
a) cultivation of human pluripotent stem cells in feeder-free conditions;
b) exposure of said cells to neuronal induction medium;
c) mechanical isolation of partially differentiated cells; and
d) further expansion and maintenance of said cells until maturation.

### Claim 52 (depends on 51)

The cells of claim 51, wherein the cells express neural stem cell markers selected from the group consisting of: SOXB1-family NES, MSH-1, CXCR4, CCND1, LHX2, PAX6 and GAP43.

### Claim 53 (depends on 51)

The cells of claim 51, wherein the neuronal stem cells maintain the neuronal phenotype for at least 30 passages.

### Claim 54 (depends on 51)

The cells of claim 51, wherein the neuronal stem cells can differentiate into neuronal cells.

### Claim 55 (depends on 54)

The cells of claim 54, wherein the neuronal cells are selected from the group consisting of neurons, astrocytes and oligodendrocytes.

### Claim 56

A method of treating a neurologic disorder using neuronal stem cells derived from parthenogenetically derived from oocytes.

### Claim 57 (depends on 56)

The method of claim 56, wherein the neurologic disorder is selected from the group consisting of: epilepsy, convulsions, neurotoxic injury, ischemia, stroke, cerebrovascular accident, brain or spinal cord trauma, physical trauma, Alzheimer's disease, senile dementia, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease, Huntington's disease, schizophrenia, neuronal damage, migraine, anxiety, major depression, manic-depressive illness, obsessive-compulsive disorder, schizophrenia and mood disorders, bipolar disorder, unipolar depression, dystonia or other movement disorders, sleep disorder, muscle relaxation.

### Claim 58 (depends on 56)

The method of claim 56, wherein the neuronal stem cells are implanted into a patient in need of such treatment.

### Claim 59

A method of differentiating neuronal stem cells, the method comprising culturing neuronal stem cells in neuronal differentiation media.

### Claim 60 (depends on 59)

The method of claim 59, wherein the neuronal differentiation media comprises:
a) Penicillin-Streptomycin-Amphotericin;
b) DMEM/F12;
c) GlutaMAX™-I; and
d) StemPro® Neural Supplement.

### Claim 61 (depends on 59)

The method of claim 59 wherein the neuronal stem cells are differentiated into a neuronal cell selected from the group consisting of: a neuron, an oligodendrocyte and an astrocyte.

### Claim 62 (depends on 59)

The differentiated cells of claim 59.

### Claim 63 (depends on 59)

The cells of claim 59, wherein the cells are differentiated from a parthenogenetically activated oocyte.
